A phase 2 study of weekly temsirolimus and bortezomib for relapsed or refractory B-cell non-Hodgkin lymphoma: A Wisconsin Oncology Network study
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A phase 2 study of weekly temsirolimus and bortezomib for relapsed or refractory B-cell non-Hodgkin lymphoma: A Wisconsin Oncology Network study
Authors
Keywords
-
Journal
CANCER
Volume 121, Issue 19, Pages 3465-3471
Publisher
Wiley
Online
2015-06-17
DOI
10.1002/cncr.29502
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Short Course of Post-Transplantation Cyclophosphamide and Bortezomib for Graft-versus-Host Disease Prevention after Allogeneic Peripheral Blood Stem Cell Transplantation Is Feasible and Yields Favorable Results: A Phase I Study
- (2015) Ahmad-Samer Al-Homsi et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study
- (2014) Michael Wang et al. BRITISH JOURNAL OF HAEMATOLOGY
- Targeting PI3-kinase (PI3K), AKT and mTOR axis in lymphoma
- (2014) James S. Blachly et al. BRITISH JOURNAL OF HAEMATOLOGY
- Clinical activity of everolimus in relapsed/refractory marginal zone B-cell lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group
- (2014) Annarita Conconi et al. BRITISH JOURNAL OF HAEMATOLOGY
- Cancer statistics, 2014
- (2014) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Potential involvement of protein phosphatase 2A in temsirolimus-mediated resensitization to cetuximab in colon cancer cells
- (2014) Ion Cristóbal et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Targeting phospho-MARCKS overcomes drug-resistance and induces antitumor activity in preclinical models of multiple myeloma
- (2014) Y Yang et al. LEUKEMIA
- Targeting the ubiquitin proteasome system in haematological malignancies
- (2013) Lisa J. Crawford et al. BLOOD REVIEWS
- Evolving strategies with immunomodulating drugs and tandem autologous/allogeneic hematopoietic stem cell transplantation in first line high risk multiple myeloma patients
- (2013) Mauricette Michallet et al. EXPERIMENTAL HEMATOLOGY
- Genetic heterogeneity of diffuse large B-cell lymphoma
- (2013) Jenny Zhang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study
- (2011) Irene M Ghobrial et al. LANCET ONCOLOGY
- Combination Therapy of Bortezomib with Novel Targeted Agents: An Emerging Treatment Strategy
- (2010) J. J. Wright CLINICAL CANCER RESEARCH
- Temsirolimus Has Activity in Non–Mantle Cell Non-Hodgkin's Lymphoma Subtypes: The University of Chicago Phase II Consortium
- (2010) Sonali M. Smith et al. JOURNAL OF CLINICAL ONCOLOGY
- Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma
- (2009) N. Di Bella et al. BLOOD
- Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre phase 2 clinical trial
- (2009) Owen A. O’Connor et al. BRITISH JOURNAL OF HAEMATOLOGY
- Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
- (2009) Georg Hess et al. JOURNAL OF CLINICAL ONCOLOGY
- Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma
- (2008) Stephen M. Ansell et al. CANCER
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started